Page last updated: 2024-09-03

sk&f 86466 and sb 216763

sk&f 86466 has been researched along with sb 216763 in 1 studies

Compound Research Comparison

Studies
(sk&f 86466)
Trials
(sk&f 86466)
Recent Studies (post-2010)
(sk&f 86466)
Studies
(sb 216763)
Trials
(sb 216763)
Recent Studies (post-2010) (sb 216763)
73393420225

Protein Interaction Comparison

ProteinTaxonomysk&f 86466 (IC50)sb 216763 (IC50)
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.55
Cyclin-dependent kinase 1Homo sapiens (human)0.55
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.55
Cyclin-A2Homo sapiens (human)0.269
Cyclin-dependent kinase 2Homo sapiens (human)0.269
Glycogen synthase kinase-3 alphaHomo sapiens (human)0.0477
Glycogen synthase kinase-3 betaHomo sapiens (human)0.0342
Cyclin-A1Homo sapiens (human)0.269
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.55

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J1

Other Studies

1 other study(ies) available for sk&f 86466 and sb 216763

ArticleYear
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
    Nature chemical biology, 2009, Volume: 5, Issue:10

    Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection

2009